TL;DR
A promising Ebola vaccine developed in 2011, effective in primates, has not been tested or used in humans for over 15 years. This delay persists despite active outbreaks and WHO interest.
A highly promising Ebola vaccine developed in 2011 has yet to be tested in humans or deployed, despite recent outbreaks and recognition by health authorities of its potential.
Virologist Thomas Geisbert and his team created a vaccine in 2011 that protected monkeys from the Bundibugyo strain of Ebola. This vaccine, based on recombinant vesicular stomatitis virus (rVSV), showed strong protection in primates, with no symptoms observed in vaccinated animals while unvaccinated ones succumbed to the disease.
Despite these promising results, the vaccine has not advanced to human trials or been used in outbreak responses. Geisbert states it remains ‘sitting on the shelf’ due to lack of funding and commercial interest, as Ebola vaccines are not seen as profitable. The World Health Organization has identified Geisbert’s vaccine as the most promising candidate for controlling current Ebola outbreaks in Central and East Africa, where hundreds of infections and numerous deaths are reported.
The vaccine’s development was initially driven by U.S. defense interests post-9/11, aiming to counter biological threats. It was later recognized as a potential tool during the 2013-2016 West Africa epidemic, which led to the deployment of Merck’s Ervebo vaccine—based on similar technology—for Zaire strain Ebola. However, Geisbert’s vaccine, effective against multiple strains including Bundibugyo, has not been publicly tested in humans or produced at scale, limiting its availability during ongoing crises.
Why the vaccine’s delay impacts current Ebola control efforts
The fact that a highly effective Ebola vaccine has remained unused for over 15 years highlights a significant gap in global health preparedness. Despite its proven success in animal studies and recognition by WHO, the vaccine has not been brought to human trials or mass production, leaving a potentially critical tool unavailable during active outbreaks. This situation underscores ongoing issues with funding, commercial interest, and the prioritization of neglected diseases, which can hinder rapid responses to emerging health crises.
As Ebola continues to cause outbreaks with high mortality rates, the absence of this vaccine limits options for containment and prevention. The delay also raises questions about how scientific advancements are translated into public health action, especially for diseases affecting regions with limited market incentives.
Ebola vaccine development kit
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Historical development and missed opportunities in Ebola vaccine progress
The development of Geisbert’s Ebola vaccine began in the early 2000s as a U.S. defense project aimed at countering biological threats. In 2003, it demonstrated protection in monkeys, but commercial interest was minimal due to the low market for Ebola vaccines, which are not profitable for pharmaceutical companies. Subsequent studies in 2009 expanded its potential to protect against multiple Ebola strains, including Bundibugyo, which caused sporadic outbreaks with lower mortality rates.
The 2013-2016 West Africa epidemic, which infected over 28,000 people and killed more than 11,000, intensified global efforts to develop effective vaccines. Merck’s Ervebo, based on similar technology, was developed and deployed for the Zaire strain, demonstrating the vaccine’s potential. However, Geisbert’s vaccine, which could target multiple strains including Bundibugyo, was not advanced at that time, partly due to funding constraints and perceived lower threat levels from less deadly strains.
Despite recent outbreaks, including hundreds of cases and deaths in Central and East Africa, the vaccine remains untested in humans. The ongoing crisis highlights the missed opportunity to utilize a promising candidate that could enhance outbreak containment efforts.
“We’ve got the rVSV Bundibugyo vaccine sitting on the shelf. It’s ready, but it’s not being used.”
— Thomas Geisbert, virologist at the University of Texas Medical Branch
Recombinant Vaccinia virus Cell surface-binding protein (D8L) (Recombinant Protein)
Source: E Coli or Yeast
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Unresolved questions about vaccine deployment and testing
It remains unclear why the vaccine has not progressed to human trials after such promising animal data, and whether efforts are underway to change this. Details about current funding, regulatory hurdles, or political will are not fully available, and it is uncertain if the vaccine will be tested or deployed in the near future.
Crisis in the Red Zone: The Story of the Deadliest Ebola Outbreak in History, and of the Viruses to Come
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Next steps for vaccine development and outbreak response
Efforts are ongoing to secure funding and regulatory approval for testing Geisbert’s vaccine in humans. The Coalition for Epidemic Preparedness Innovations has offered support to prepare manufacturing, but no definitive timeline is set. Meanwhile, health authorities continue to rely on existing vaccines and containment measures, leaving the potential of this promising candidate largely untapped.
Vaccine Nation: Science, reason and the threat to 200 years of progress
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
Why has the Ebola vaccine developed in 2011 not been used in outbreaks?
The vaccine has not been deployed due to a lack of funding, commercial interest, and regulatory hurdles, despite proven efficacy in animals.
Could this vaccine help control current Ebola outbreaks?
It has the potential to do so, especially given its effectiveness in primates, but it has not yet been tested or approved for human use.
What are the main barriers to deploying this vaccine?
Funding, lack of commercial incentives, and regulatory processes are the primary barriers preventing human trials and widespread use.
Is there any ongoing effort to test or distribute the vaccine now?
Support from organizations like CEPI is in place to prepare for testing, but no immediate plans for human trials or distribution have been announced.
How does this delay affect global Ebola preparedness?
The delay limits the availability of a highly effective tool during outbreaks, highlighting systemic issues in translating scientific advances into public health action.
Source: WIRED
